Convincing effects of clonidine on neurohumoral withdrawal symptoms during antagonist-supported detoxification of opioid addicts.
Department of Anesthesiology & Pain Management University of Texas Southwestern Medical Center at Dallas Dallas, TX Department of Anesthesiology Cedars Sinai Medical Center in Los Angeles Los Angeles, CA.
Paul F
PF
White
Ronald H
RH
Wender
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D003000:Clonidine / Q000627:therapeutic use*; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000503:physiopathology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D000316:Adrenergic alpha-Agonists; D009292:Narcotic Antagonists; D003000:Clonidine